曲美他嗪与阿托伐他汀联用对急性冠状动脉综合征患者血脂影响.docVIP

曲美他嗪与阿托伐他汀联用对急性冠状动脉综合征患者血脂影响 　　【摘要】 目的 观察曲美他嗪与阿托伐他汀联用对急性冠状动脉综合征（ACS）患者血脂水平的影响， 探讨曲美他嗪与阿托伐他汀在急性冠状动脉综合征治疗中的作用。方法 98例急性冠状动脉综合征患者， 采用单盲、随机、对照方法将其分为曲美他嗪与阿托伐他汀治疗组（51例， 曲美他嗪片60 mg/d， 阿托伐他汀片20 mg/d， 发病24 h内开始服用）和对照组（47例， 每日口服安慰剂）， 而两组其他治疗方法相同， 治疗4周。分别于治疗前后检测患者血脂的浓度， 血脂采用酶法测定。结果 治疗4周后， 治疗组患者总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）浓度与治疗前比较， 显著降低， 高密度脂蛋白胆固醇（HDL-C）浓度与治疗前比较， 显著升高， 差异有统计学意义（Plt;0.01）， 而对照组治疗前血脂浓度比较， 差异无统计学意义（Pgt;0.05）。治疗后两组TC、TG、LDL-C、HDL-C浓度比较， 差异具有统计学意义（Plt;0.05）。结论 曲美他嗪与阿托伐他汀联用ACS患者可明显改善血脂。 　　【关键词】 曲美他嗪;阿托伐他汀;血脂;急性冠状动脉综合征 　　DOI：10.14163/j.cnki.11-5547/r.2015.03.015 　　Influence of trimetazidine combined with atorvastatin on blood lipid in patients with acute coronary syndrome WANG Lei. Department of Cardiology， The First People’s Hospital of Shangqiu City， Shangqiu 476100， China 　　【Abstract】 Objective To observe the influence of trimetazidine combined with atorvastatin on blood lipid in patients with acute coronary syndrome （ACS）， and to explore the effect of trimetazidine combined with atorvastatin in the treatment of ACS. Methods A total of 98 patients with ACS were divided into trimetazidine combined with atorvastatin group （51 cases， 60 mg/d of trimetazidine， 20 mg/d of atorvastatin， administration within 24 d of attack） and control group （47 cases， placebo through daily oral administration）， according to single-blind， random， control method. The other treatments in the two groups were the same. The treatment lasted for 4 weeks， and the concentration of blood lipid was detected by enzymic method before and after treatment. Results After 4-week treatment， the treatment group had remarkably decreased total cholesterol （TC）， triglyceride （TG）， and low-density lipoprotein cholesterol （LDL-C） than those before treatment， while it had increased high-density lipoprotein cholesterol （HDL-C） than that before treatment. The differences had statistical significance （Plt;0.01）. However， there was no statistically significant difference of blood lipid concentration bef